#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13516	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2009	668.3	0	.	n	.	0	A800G	SNP	800	800	A	1055	1055	G	815	G,A	748,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13516	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2009	668.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1705	1705	T	769	T,C	696,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13516	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2009	668.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1439	1439	C	851	C	770	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24840	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3374	732.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1603	1603	A	801	A,G	746,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24840	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3374	732.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2237	2237	C	766	C,T	696,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24840	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3374	732.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2311	2311	A	777	A,G	725,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24840	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3374	732.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2863	2863	C	796	C	739	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2010	folP	855	855	100.0	folP.l15.c4.ctg.1	1449	137.8	1	SNP	p	R229S	1	.	.	685	687	AGC	995	997	AGC	188;190;193	A;G;C,T	174;174;176,1	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5388	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3443	156.2	1	SNP	p	S91F	1	.	.	271	273	TTC	596	598	TTC	185;185;183	T;T;C	173;173;169	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5388	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3443	156.2	1	SNP	p	D95G	1	.	.	283	285	GGC	608	610	GGC	185;186;184	G;G;C	171;174;173	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5388	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3443	156.2	1	SNP	p	G95N	0	.	.	283	285	GGC	608	610	GGC	185;186;184	G;G;C	171;174;173	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1574	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1214	128.7	1	SNP	p	G45D	0	.	.	133	135	GGC	415	417	GGC	179;181;183	G;G;C	165;161;165	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	840	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1185	70.8	0	.	n	.	0	A197.	DEL	197	197	A	668	668	A	227	A	206	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4876	parC	2304	2304	99.87	parC.l6.c30.ctg.1	3028	160.3	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1561	1563	GTC	195;196;198	G,A;T;C	183,1;184;187	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4876	parC	2304	2304	99.87	parC.l6.c30.ctg.1	3028	160.3	1	SNP	p	D86N	0	.	.	256	258	GAC	667	669	GAC	198;196;195	G;A;C	182;176;182	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4876	parC	2304	2304	99.87	parC.l6.c30.ctg.1	3028	160.3	1	SNP	p	S87R	1	.	.	259	261	CGT	670	672	CGT	197;197;197	C;G;T,C	182;184;179,1	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4876	parC	2304	2304	99.87	parC.l6.c30.ctg.1	3028	160.3	1	SNP	p	R87W	0	.	.	259	261	CGT	670	672	CGT	197;197;197	C;G;T,C	182;184;179,1	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4876	parC	2304	2304	99.87	parC.l6.c30.ctg.1	3028	160.3	1	SNP	p	R87I	0	.	.	259	261	CGT	670	672	CGT	197;197;197	C;G;T,C	182;184;179,1	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4876	parC	2304	2304	99.87	parC.l6.c30.ctg.1	3028	160.3	1	SNP	p	S88P	0	.	.	262	264	TCC	673	675	TCC	194;194;196	T;C;C	177;178;184	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4204	parE	1986	1986	99.95	parE.l6.c30.ctg.1	2516	166.3	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1300	1302	TGC	201;206;203	T;G,A;C	177;184,1;179	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4204	parE	1986	1986	99.95	parE.l6.c30.ctg.1	2516	166.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1510	1512	GGC	204;201;200	G;G;C	184;179;179	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3656	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2462	147.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1354	1356	GCA	206;209;210	G;C;A	189;192;193	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3656	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2462	147.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1357	1359	ATC	212;212;214	A;T;C	191;191;195	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3656	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2462	147.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1369	1371	GTG	218;213;209	G;T;G	200;194;192	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3656	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2462	147.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1369	1371	GTG	218;213;209	G;T;G	200;194;192	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3656	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2462	147.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1873	1875	ACC	160;159;161	A;C;C	144;144;149	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3656	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2462	147.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1927	1929	GCG	175;175;178	G;C,G;G	163;144,2;150	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3656	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2462	147.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1927	1929	GCG	175;175;178	G;C,G;G	163;144,2;150	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3656	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2462	147.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2050	2052	GGC	189;189;187	G;G;C	177;176;177	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3656	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2462	147.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2059	2061	GGC	179;177;182	G;G;C	166;165;165	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3656	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2462	147.8	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2077	2079	TCG	170;170;167	T,G,C;C,T,G;G	113,6,1;134,1,1;136	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5374	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3017	177.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1574	1576	CCG	193;195;193	C;C;G	172;179;172	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2388	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1749	135.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	490	490	C	161	C	147	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2604	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1530	169.3	0	.	p	.	0	N38E	NONSYN	112	114	AAT	463	465	GAA	206;204;202	G;A;A	190;191;188	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2604	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1530	169.3	0	.	p	.	0	N134D	NONSYN	400	402	AAT	751	753	GAT	214;212;212	G;A;T	194;193;193	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2604	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1530	169.3	0	.	p	.	0	P175S	NONSYN	523	525	CCA	874	876	TCA	215;216;215	T;C;A	187;189;192	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2604	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1530	169.3	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1003	1005	GTC	193;193;195	G;T,A;C	184;183,1;185	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2604	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1530	169.3	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1333	1335	GCA	201;201;202	G;C;A	186;184;185	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2604	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1530	169.3	1	SNP	p	G120K	1	.	.	358	360	AAG	709	711	AAG	211;212;217	A;A;G	196;197;199	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2604	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1530	169.3	1	SNP	p	A121D	1	.	.	361	363	GAC	712	714	GAC	219;218;217	G;A;C	200;200;199	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2604	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1530	169.3	1	SNP	p	D121N	0	.	.	361	363	GAC	712	714	GAC	219;218;217	G;A;C	200;200;199	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9432	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4727	198.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1881	1883	AAT	200;198;199	A;A;T	191;189;189	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1036	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1004	102.7	1	SNP	p	V57M	1	.	.	169	171	ATG	539	541	ATG	205;204;206	A;T;G	188;189;190	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
